Status:
COMPLETED
Study of Immune Response in Obesity and Type 2 Diabetes
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Obesity
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
There is a link between activation of the immune response inducing chronic inflammation and both obesity and type 2 diabetes. To date, however, the cause(s) of this inflammation, the mechanisms of the...
Eligibility Criteria
Inclusion
- Patient-control who have given written informed consent Patient-control who are covered by the National Health Insurance Agency Patient-control \> 18 years old
- The criteria to classify patients into groups will be as follows:
- Group 1- Obese diabetics BMI \> 30 Kg /m2 AND fasting glycemia \> 1.26 g/L AND Triglycerides \>1.5g/L AND HDL \<0.4g/L (men), \<0.5g/L (women) Group 2- Obese non-diabetics without metabolic syndrome BMI \> 30 Kg /m2 AND fasting glycemia \< 1.10 g/L AND Triglycerides \<1.5g/L AND HDL \>0.4g/L (men), \>0.5g/L (women) Group 3- Healthy Subjects BMI \< 25 Kg/m² AND fasting glycemia \< 1.10g/L AND Triglycerides \<1.5g/L
Exclusion
- Persons not covered by the National Health Insurance Agency Patients who presented a recent infection, or cancer or patients treated with corticosteroids or anti-inflammatory drugs. Patients with diabetes following an overload disease (hemochromatosis) or due to a disease of the pancreas Chronic infection Pregnant women Patients on the following treatments (glitazone: Actos, Avendia; GLP1 Agonist: Byetta, Victoza; Fibrates) Patients presenting severe renal insufficiency with clearance\<30ml/min
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT01907399
Start Date
September 1 2010
End Date
April 1 2014
Last Update
December 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Dijon
Dijon, France, 21079